Literature DB >> 18644976

Frequency and timing of loss of imprinting at 11p13 and 11p15 in Wilms' tumor development.

Keith W Brown1, Frances Power, Beth Moore, Adrian K Charles, Karim T A Malik.   

Abstract

Epigenetic changes occur frequently in Wilms' tumor (WT), especially loss of imprinting (LOI) of IGF2/H19 at 11p15. Our previous results have identified imprinted transcripts (WT1-AS and AWT1) from the WT1 locus at 11p13 and showed LOI of these in some WTs. In this article, we set out to test the relationship between LOI at 11p13 and 11p15 and their timing in WT progression relative to other genetic changes. We found a higher level (83%) of 11p13 LOI in WT than of 11p15 LOI (71%). There was no correlation between methylation levels at the 11p13 and 11p15 differentially methylated regions or between allelic expression of WT1-AS/AWT1 and IGF2. Interestingly, retention of normal imprinting at 11p13 was associated with a small group of relatively late-onset, high-stage WTs. An examination of genetic and epigenetic alterations in nephrogenic rests, which are premalignant WT precursors, showed that LOI at both 11p13 and 11p15 occurred before either 16q loss of heterozygosity (LOH) or 7p LOH. This suggests that these LOH events are very unlikely to be a cause of LOI but that LOH may act by potentiating the effects of overexpression of IGF2 and/or WT1-AS/AWT1 that result from LOI.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18644976     DOI: 10.1158/1541-7786.MCR-08-0002

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  9 in total

1.  The prevalence of loss of imprinting of H19 and IGF2 at birth.

Authors:  Rebecca C Rancourt; Holly R Harris; Ludovic Barault; Karin B Michels
Journal:  FASEB J       Date:  2013-04-25       Impact factor: 5.191

2.  WT1 expression is increased in primary fibroblasts derived from Dupuytren's disease tissues.

Authors:  Justin Crawford; Christina Raykha; Daevina Charles; Bing Siang Gan; David B O'Gorman
Journal:  J Cell Commun Signal       Date:  2015-06-30       Impact factor: 5.782

Review 3.  Imprinted genes in myeloid lineage commitment in normal and malignant hematopoiesis.

Authors:  L Benetatos; G Vartholomatos
Journal:  Leukemia       Date:  2015-02-23       Impact factor: 11.528

4.  Loss of imprinting of IGF2 and the epigenetic progenitor model of cancer.

Authors:  Mark B Leick; Christopher J Shoff; Erwin C Wang; Jaclyn L Congress; G Ian Gallicano
Journal:  Am J Stem Cells       Date:  2011-08-19

5.  Constitutional and somatic methylation status of DMRH19 and KvDMR in Wilms tumor patients.

Authors:  Leila C A Cardoso; Jair A Tenorio Castaño; Hanna S Pereira; Maria Angélica de F D Lima; Anna Cláudia E Dos Santos; Paulo S de Faria; Sima Ferman; Héctor N Seuánez; Julián B Nevado; José Carlos Cabral de Almeida; Pablo Lapunzina; Fernando R Vargas
Journal:  Genet Mol Biol       Date:  2012-11-09       Impact factor: 1.771

6.  Dysregulated methylation at imprinted genes in prostate tumor tissue detected by methylation microarray.

Authors:  Daniel I Jacobs; Yingying Mao; Alan Fu; William Kevin Kelly; Yong Zhu
Journal:  BMC Urol       Date:  2013-07-26       Impact factor: 2.264

7.  Frequent long-range epigenetic silencing of protocadherin gene clusters on chromosome 5q31 in Wilms' tumor.

Authors:  Anthony R Dallosso; Anne L Hancock; Marianna Szemes; Kim Moorwood; Laxmi Chilukamarri; Hsin-Hao Tsai; Abby Sarkar; Jonathan Barasch; Raisa Vuononvirta; Chris Jones; Kathy Pritchard-Jones; Brigitte Royer-Pokora; Sean Bong Lee; Ceris Owen; Sally Malik; Yi Feng; Marcus Frank; Andrew Ward; Keith W Brown; Karim Malik
Journal:  PLoS Genet       Date:  2009-11-26       Impact factor: 5.917

8.  ALKBH5 gene polymorphisms and Wilms tumor risk in Chinese children: A five-center case-control study.

Authors:  Rui-Xi Hua; Jiabin Liu; Wen Fu; Jinhong Zhu; Jiao Zhang; Jiwen Cheng; Suhong Li; Haixia Zhou; Huimin Xia; Jing He; Zhenjian Zhuo
Journal:  J Clin Lab Anal       Date:  2020-02-24       Impact factor: 2.352

9.  The epithelial splicing regulator ESRP2 is epigenetically repressed by DNA hypermethylation in Wilms tumour and acts as a tumour suppressor.

Authors:  Danny Legge; Ling Li; Whei Moriarty; David Lee; Marianna Szemes; Asef Zahed; Leonidas Panousopoulos; Wan Yun Chung; Yara Aghabi; Jasmin Barratt; Richard Williams; Kathy Pritchard-Jones; Karim T A Malik; Sebastian Oltean; Keith W Brown
Journal:  Mol Oncol       Date:  2021-09-28       Impact factor: 6.603

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.